Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD) announced the appointment of Dr. Osama Hamdy as a consultant on their advisory board. Dr. Hamdy, a senior endocrinologist and medical director at the Joslin Diabetes Center, will advise on key opinion leader studies focused on diabetes and metabolic health using Nemaura's glucose monitoring technology. The collaboration aims to enhance patient health through non-invasive treatments, leveraging Dr. Hamdy's expertise in obesity management and digital health. Nemaura's products, including sugarBEAT^®, are positioned in a growing global diabetes market projected to reach $59 billion by 2025.

Positive

• Dr. Osama Hamdy's expertise in diabetes and obesity management strengthens Nemaura's advisory team.
• The collaboration could enhance the development of non-invasive glucose monitoring technologies.
• Nemaura's participation in key opinion leader studies may lead to improved patient health outcomes.

Negative

• None.

Loughborough, England, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that Dr. Osama Hamdy, MD, PhD, has joined their advisory board as consultant, and is expected to partake on and advise on Key Opinion leader studies in both the Diabetes field and Metabolic Health field using Nemaura’s glucose monitoring technology in the near future.

Dr. Hamdy is a senior endocrinologist and medical director, Obesity Clinic Program at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School. Dr. Hamdy is a world renowned thought leader in the field of obesity management in diabetes, medical nutrition and digital health. Many of his discoveries and innovations are currently shaping these fields. His professional work focuses on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss, and he is currently investigating the cardiovascular benefits of short- and long-term weight reduction in obese individuals with and without type 2 diabetes.

“We are truly gratified to have a practicing clinician that has changed the real-world treatment of diabetes management as an advisor to us for some upcoming KOL studies,” said Nemaura CEO Dr. Faz Chowdhury. “These studies will allow us to better impact patient health, and we expect the counsel and input from Dr. Hamdy to be meaningful in helping us to deliver non-invasive treatment options to further enrich people’s lives.”

Dr. Hamdy has translated the successful clinical research results of two landmark studies in diabetes into a clinical practice model through the creation of Joslin’s Why WAIT (Weight Achievement and Intensive Treatment) Program, which serves, in part, as the basis for Nemaura’s lifestyle program, BEAT^®diabetes.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

What is the significance of Dr. Osama Hamdy joining Nemaura Medical as a consultant?

Dr. Hamdy's expertise in diabetes management may enhance Nemaura's research and development efforts in glucose monitoring.

When was the announcement regarding Dr. Hamdy's appointment made?

The announcement was made on September 17, 2021.

How does Dr. Hamdy's background benefit Nemaura Medical?

Dr. Hamdy is a renowned expert in obesity management and diabetes treatment, which could guide Nemaura's product development and clinical research.

What are Nemaura's key products mentioned in the press release?

The key products mentioned are sugarBEAT^® and proBEAT^™, both targeting diabetes management.

What is Nemaura Medical's market focus?

Nemaura focuses on the diabetes and wearable health technology sectors, with significant market growth projected.